title: Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective.
abstract: OBJECTIVE
  The EPHESUS study demonstrated that aldosterone blockade with eplerenone decreased mortality in patients with left ventricular systolic dysfunction (LVSD) and heart failure after acute myocardial infarction (AMI). The EPHESUS pharmacoeconomic analysis was performed to evaluate the cost-effectiveness of eplerenone in the Swiss setting.
  
  
  METHODS
  A total of 6,632 patients with LVSD and heart failure after AMI were randomized to eplerenone or placebo and followed for a mean of 16 months. The co-primary endpoints were all-cause death and the composite of cardiovascular death/cardiovascular hospitalization. The evaluation of resource use included hospitalizations, outpatient services, and medications. Survival beyond the trial period was estimated using data from the Framingham Heart Study, the Saskatchewan Health database, and the Worcester Heart Attack Registry. The incremental cost-effectiveness of eplerenone in cost per life-year and quality-adjusted life-year gained was estimated. The perspective of the Swiss third party payers was used. Daily treatment costs of eplerenone were set at CHF 3.88. All other resources were valued on the basis of official tariffs. Discounting of the results was performed at a rate of 3%.
  
  
  RESULTS
  The number of life-years gained with eplerenone was 0.1083 based on Framingham, 0.0661 with Saskatchewan and 0.1518 with Worcester survival estimates. Total costs were CHF 1,028 higher over the trial period in the eplerenone arm, due to drug cost. The incremental cost-effectiveness ratio was CHF 10,145 per life-year gained with Framingham, CHF 16,178 with Saskatchewan, and CHF 7,693 with Worcester survival estimates. The corresponding costs per QALY were CHF 15,219, CHF 23,965 and CHF 11,337, respectively.
  
  
  CONCLUSIONS
  Eplerenone is effective in reducing mortality and, in Switzerland, is also cost-effective in increasing years of life for patients with LVSD after AMI.
authors.affiliation: Institute of Social- and Preventive Medicine, University of Zurich, Gloriastrasse 18a, CH-8006 Zurich, Switzerland. thomas.szucs@ifspm.unizh.ch
authors.forename: Thomas D
authors.initials: TD
authors.lastname: Szucs
authors.forename: Majbrit V
authors.initials: MV
authors.lastname: Holm
authors.forename: Matthias
authors.initials: M
authors.lastname: Schwenkglenks
authors.forename: Zefeng
authors.initials: Z
authors.lastname: Zhang
authors.forename: William S
authors.initials: WS
authors.lastname: Weintraub
authors.forename: Michel
authors.initials: M
authors.lastname: Burnier
authors.forename: Paul
authors.initials: P
authors.lastname: Erne
mesh_terms: D000328:Adult; D000368:Aged; D003362:Cost-Benefit Analysis; D000077545:Eplerenone; D005260:Female; D017048:Health Care Costs; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications*; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000401:mortality
chemical_list: D013148:Spironolactone; D000077545:Eplerenone